Ucb
UCB, or UCB S.A., is a global biopharmaceutical company headquartered in Belgium. Founded in 1928, UCB has established itself as a leader in the biopharmaceutical industry, focusing on the development of innovative therapies for neurological and immunological disorders. With a strong presence in Europe and North America, UCB is dedicated to improving the lives of patients through its core products, including treatments for epilepsy, Parkinson's disease, and autoimmune conditions. The company is renowned for its commitment to research and development, which has led to significant milestones such as the launch of several groundbreaking therapies. UCB's unique approach combines advanced science with patient-centric solutions, positioning it as a key player in the global healthcare market. With a robust pipeline and a focus on unmet medical needs, UCB continues to make notable strides in the biopharmaceutical landscape.
DitchCarbon Score
How does Ucb's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ucb's score of 89 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ucb's reported carbon emissions
In 2023, UCB reported total greenhouse gas emissions of approximately 63,165,000 kg CO2e, with emissions distributed across various scopes: 20,547,000 kg CO2e (Scope 1), 17,867,000 kg CO2e (Scope 2), and 63,165,000 kg CO2e (Scope 3). Notably, UCB has set ambitious climate commitments, aiming for net-zero emissions across its value chain by 2045. For near-term targets, UCB plans to reduce absolute Scope 1 and 2 emissions by 73% by 2030 from a 2019 baseline, while also targeting a 48% reduction in Scope 3 emissions within the same timeframe. This includes significant categories such as business travel and purchased goods and services. Furthermore, UCB aims for 80% of its suppliers, based on emissions from purchased goods and services, to have science-based targets by 2028. Long-term, UCB commits to a 90% reduction in both Scope 1 and 2 emissions and Scope 3 emissions by 2045, again using 2019 as the baseline year. These targets align with industry standards for climate action and demonstrate UCB's commitment to sustainability and reducing its carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 34,733,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 31,367,000 | 00,000,000 | 0,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 0,000 |
| Scope 3 | - | - | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ucb is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
